Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology
Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in delivering Antibody ...
Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced its innovative drug development ...
Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs
Molecular Partners' DARPin platform shows promise, but future funding is uncertain. Learn why MOLN stock could be a risky, ...
Korea Joongang Daily on MSN16h
Ulcerative colitis drug Zymfentra to generate fifth of Celltrion's 2025 revenue
Celltrion plans to generate 20 percent of its annual revenue this year from its original drug Zymfentra as part of its ...
USA News Group: Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
Issued on behalf of Oncolytics Biotech Inc. USA News Group News Commentary VANCOUVER, BC, Jan. 15, 2025 /PRNewswire/ -- As 2025 begins, the American Association for Cancer Research ...
BioSpace5h
2025 Investment to Swing Toward I&I, Obesity, More: Experts
As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...
FierceBiotech19h
JPM25: GSK’s CSO shares science strategy behind deal-heavy year
And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...